GlassScriptPhysician profile
Howard J Solomon
NPI 1295707404
$14,454.12
in general payments reported to CMS, 2019-2025
42 companies · $2,703 in 2025
The $2,703 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,389 · 2020: $925 · 2021: $1,748 · 2022: $2,083 · 2023: $2,405 · 2024: $3,201 · 2025: $2,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,280 · Education: $28.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,279.87 |
| Education | $28.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,327.62 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,492.96 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $2,237.14 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $780.80 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Qol Medical, LLC | $765.33 | 2020-2025 | Sucraid, Sucraid |
| Pfizer INC. | $439.56 | 2019-2025 | |
| Daiichi Sankyo INC. | $402.16 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $392.72 | 2019-2024 | Dificid |
| Lucid Diagnostics INC. | $346.74 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $293.58 | 2019-2025 | Rebyota |
| Ardelyx, INC. | $276.82 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $270.79 | 2022-2025 | |
| Organon LLC | $202.89 | 2021-2025 | Renflexis, Hadlima, Nexplanon |
| Ipsen Biopharmaceuticals, INC | $202.18 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $186.25 | 2024-2025 | Omvoh |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.